

1 **Title:** The Royal College of Ophthalmologists' National Ophthalmology Database study
2 of cataract surgery: Report 9, Risk factors for posterior capsule opacification

3 **Authors:** Paul HJ Donachie^{1,2}, Beth L Barnes¹, Martina Olaitan¹, John M Sparrow^{1,3} John
4 C Buchan^{1,4,5}

5

6 1. The Royal College of Ophthalmologists' National Ophthalmology Audit, 18
7 Stephenson Way, London NW1 2HD, UK

8 2. Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, GL53 7AN, UK

9 3. Bristol Eye Hospital, Lower Maudlin Street, Bristol, BS1 2LX, UK

10 4. International Centre for Eye Health, London School of Hygiene and Tropical Medicine,
11 Keppel Street, London, WC1E 7HT

12 5. Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, LS9 7TF

13

14 **Corresponding Author:**

15 John C Buchan

16 International Centre for Eye Health

17 London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT

18 Telephone: +44 (0) 7543943933

19 Email: john.buchan@lshtm.ac.uk

20

21 **Short Heading:**

22 NOD Posterior Capsule Opacity Risk Factor Analysis

23

24

25

26 **Summary**

27 What was known before:

- 28 - Posterior Capsule Opacification (PCO) is the most common long-term post-
29 operative adverse occurrence after cataract surgery
- 30 - Factors associated with increased risk of PCO can relate to the patient or their
31 eye, the surgery, or the intra-ocular lens (IOL) material and design, such as the
32 well-established superiority of a square-edged IOL in preventing PCO

33

34 What this study adds:

- 35 - This is the largest published series investigating risk factors for PCO
- 36 - The six month, one, three, five and nine year observed rates of PCO were 2.1%,
37 4.0%, 18.0%, 31.2% and 43.5% respectively
- 38 - Risk factors that increased the risk of developing PCO included hydrophilic IOL
39 material, an axial length >26 mm, high myopia, previous vitrectomy,
40 uveitis/synechiae, younger age and female gender

41

42 **Key Words:** cataract, posterior capsule opacification, Nd YAG laser capsulotomy

43

44

45 **Conflict of Interest:** No authors have any conflict of interest to declare

46

47 **Funding:** This analysis was funded by an unconditional grant from Alcon (Geneva,
48 Switzerland) in support of the Royal College of Ophthalmologists National
49 Ophthalmology Database cataract audit. The funders did not have any editorial
50 oversight, right of veto or academic input into the analysis or write up of this work.

51

52 **Word count = 3351**

53

54

55 **Abstract (words = 233)**

56 **Background / Objectives**

57 Posterior Capsule Opacification (PCO) is the most common long-term post-operative
58 adverse occurrence after cataract surgery often requiring treatment with YAG laser
59 posterior capsulotomy. This study aimed to identify potential risk factors, known at the
60 time of cataract surgery, that influence the development of PCO.

61

62 **Subject / Methods**

63 A retrospective study of publicly funded cataract surgery from The Royal College of
64 Ophthalmologists' National Ophthalmology Database. Eligible for analysis were 601 084
65 cataract operations performed in 58 participating centres.

66

67 **Results**

68 The 601 084 operations were performed on 291 411 (48.5%) left eyes and 309 673
69 (51.5%) right eyes from 448 510 patients by 2 566 surgeons. Post-cataract PCO was
70 recorded for 65 210 (10.9%) eyes and the six month, one, three, five and nine year
71 observed rates of PCO were 2.1%, 4.0%, 18.0%, 31.2% and 43.5% respectively. Different
72 PCO profiles were observed between IOL designs and materials and the identified risk
73 factors that increased the risk of developing PCO included hydrophilic IOL material, axial
74 length >26 mm, the presence of high myopia and implantation of lower IOL powers,
75 previous vitrectomy surgery and uveitis/synechiae, along with younger age and female
76 gender.

77

78 **Conclusions**

79 Many factors influence the development of PCO relating to the patient, the eye, the lens
80 and the surgery. Some factors are modifiable such as IOL material and design, therefore
81 the opportunity exists to attempt to reduce PCO rates, benefitting patients and the UK
82 NHS.

83

84

85 **Introduction**

86 Cataract surgery is the most frequently performed surgical procedure in the UK, with
87 around 472 000 operations funded by the NHS in England and Wales during the 2018-
88 2019 national cataract audit year ([www.nodaudit.org.uk/resources/publications-
89 annual-report](http://www.nodaudit.org.uk/resources/publications-annual-report)). Posterior capsule opacification (PCO) is the most frequent long-term
90 adverse occurrence after cataract surgery, often requiring treatment with YAG laser
91 posterior capsulotomy. As a consequence, despite YAG laser being a frequently
92 performed and low risk procedure, posterior capsule rates are of significant public
93 health interest due to the visual impairment they cause prior to treatment, and the
94 resources directed towards their diagnosis and management which could be redeployed
95 if rates were reduced.

96

97 PCO rates have been variously reported depending on definitions used and the length
98 of follow-up in different studies. PCO has been linked to patient factors, cataract surgical
99 techniques and implanted intra-ocular lens (IOL) materials or design, such as the
100 established reduction in PCO rates seen with square-edged IOL designs compared to
101 round edge IOL shown by systematic review of randomised controlled trials (RCT).(1, 2).
102 In addition to RCT, real-world PCO rates and risk factors have been reported.(3, 4).

103

104 The Royal College of Ophthalmologists (RCOphth) National Ophthalmology Database
105 (NOD) Cataract Audit accesses post-operative records from the majority of UK cataract
106 service providers, and therefore provides the opportunity to explore PCO rates and risk

107 factors at a scale not previously reported to identify potential targets for interventions
108 to reduce PCO rates nationally.

109

110 **Subjects and Methods**

111 The RCOphth NOD receives anonymised data from around 70% of centres providing
112 publicly funded cataract surgery in England, Wales and Guernsey as described in other
113 publications(5) and on the audit website (www.nodaudit.org.uk). Only electronic
114 medical record (EMR) enabled centres are included in this analysis due to the in-house
115 data collection systems submitting follow-up data at one fixed time point after surgery,
116 instead of serial postoperative data. Only data from institutions providing a full range of
117 ocular services were included. Centres only providing primarily cataract-related services
118 were excluded as they have limited opportunity to see patients who are PCO-free, hence
119 would generate artificially high PCO rates if they offer YAG laser, or artificially low rates
120 if they do not provide this service. We excluded any centre that did not have records of
121 at least one case of PCO more than one month after cataract surgery, as some
122 institutions have pathways that systematically fail to capture certain outpatient activity
123 on the EMR. Operations with at least one month's follow-up are included, where the
124 follow-up data could be for any post-surgery hospital visit for either clinical assessments
125 or treatments. The study time period concerns operations performed between
126 01/04/2010 and 31/03/2018 with 31/08/2019 as the last date of any follow-up record,
127 this enabled all operations to have the opportunity for a minimum of one year and five
128 months follow-up. Each IOL was allocated a group based on model, material and IOL
129 design derived from manufacturer specifications.

130

131 Excluded from the analysis were;

132 - where no IOL was inserted

133 - IOL was not recorded

134 - IOL's that could not be allocated to the IOL model grouping

135 - operations with missing patient age at surgery

136 - operations with missing IOL power as this could indicate the eye was left aphakic

137 - operations where the recorded IOL power is outside the range of -10 to +40
138 dioptres (most likely indicative of a data entry error)

139 - eyes with a recorded axial length measurement <18 mm as these could be
140 abnormal eyes or data entry errors

141 - centres with fewer than 50 phacoemulsification operations satisfying the above
142 criteria.

143

144 The data was recorded on the Medisoft EMR system (Medisoft Ophthalmology,
145 Medisoft Limited, Leeds, UK, www.medisoft.co.uk) or the Open Eyes EMR system
146 (www.openeyes.org.uk). Anonymized database analyses of this type do not require
147 ethical permission due to being viewed as audit or service evaluation (see
148 [http://www.hra.nhs.uk/research-community/before-you-apply/determinewhether-
149 your-study-is-research/](http://www.hra.nhs.uk/research-community/before-you-apply/determinewhether-your-study-is-research/)). This study was conducted in accordance with the declaration
150 of Helsinki, and the UK's Data Protection Act.

151

152

153 **PCO definition**

154 Post-cataract PCO was identified from recorded post-operative complications, post-
155 cataract diagnoses or post-cataract surgical records (for YAG posterior capsulotomy)
156 from eight days post-cataract surgery to the date of the last record of any post-cataract
157 assessment for the patient.

158 The first record of PCO post-cataract surgery is used as the index “event” for PCO, and
159 for non-PCO eyes the last assessment date for the patient is used as a surrogate for final
160 follow-up. As PCO can occur at different points in time, the Kaplan-Meier method with
161 the actuarial adjustment was used to graphically display the PCO (“failure event”) rates
162 over time and create PCO rates at specific post-cataract surgery time points
163 representing the cumulative probability of PCO occurring.

164

165 **PCO risk factor modelling**

166 To identify potential risk factors influencing the development of PCO, an accelerated
167 failure time Loglogistic model was fitted with robust cluster adjustment of the standard
168 error using the patients as clusters to account for patient level correlation.

169

170 The covariates considered as potential risk factors are known before cataract surgery
171 starts, except for PCR which occurs during the operation, and in nearly all cases is known
172 by the end of surgery. The idea behind limiting potential risk factors to those known by
173 the end of surgery is that at that point or the post-cataract follow-up assessment,
174 information could be provided to patients regarding their risk of PCO occurring within
175 specific post-cataract time periods. Attempts to account for specific diseases that could

176 develop between cataract surgery and PCO are not feasible with data currently
177 submitted to the RCOphth NOD.

178

179 All candidate covariates were first investigated using the Logrank test, where any
180 covariate significant at the 10% level was considered eligible for the multivariate
181 Loglogistic model, which was fitted using backwards selection from the 'full' model to
182 the 'best fitting' model by removing covariates with a significance level >1%. The use of
183 1% significance was adopted due to the increased chance of detecting very small
184 significant differences from the large sample size, and to try to minimise negative
185 impacts of possible overfitting. It is feasible this approach does not produce the best
186 model for the sample, but is practical for a very large sample where some covariates are
187 for rare diseases, and to attempt to remove covariates with minimal clinical differences
188 that otherwise could be found statistically significant if using a higher significance level.

189

190 Model diagnostics included comparison of the final model with other parametric
191 modelling approaches (Weibull, Lognormal and Exponential) and plotting Cox-Snell
192 residuals against the cumulative hazard where deviations away from the line of identity
193 imply a poorer model fit. All analysis was conducted in STATA 16 (StataCorp. 2019. *Stata*
194 *Statistical Software: Release 16*. College Station, TX: StataCorp LLC).

195

196 **Results**

197 **Patients and operation characteristics**

198 Within the study period 822 568 operations eligible for the national cataract audit were
199 performed from EMR enabled centres offering a full range of ocular services with at least
200 one case of PCO later than one-month post-cataract surgery. It was necessary to exclude
201 221 484 (26.9%) operations due to: 210 095 with <1 month of follow-up data recorded,
202 6 176 from one site where there is uncertainty about the IOL information and no follow-
203 up data since November 2016, 3 056 where we were unable to match the recorded IOL
204 to a specific IOL model, 1 291 were recorded as 'no IOL inserted', 413 with a missing IOL
205 power, 340 with no IOL recorded, 97 with IOL powers outside the range of -10 to +40
206 dioptres, 15 as the recorded axial length was <18 mm and one missing patient age at
207 surgery. The 601 084 cataract operations eligible for this analysis were performed in 58
208 participating centres, 56 English NHS Trusts, one Welsh Local Health Board and one
209 centre from Guernsey.

210

211 The 601 084 operations were performed on 291 411 (48.5%) left eyes and 309 673
212 (51.5%) right eyes from 448 510 patients by 2 566 surgeons. The operations were
213 performed by surgeons of different grades; 1 105 consultant surgeons performed 364
214 153 (60.6%) operations, 337 career grade non-consultant surgeons (associate
215 specialists, staff grades and trust doctors) performed 69 054 (11.5%) operations, 1 401
216 more experienced trainee surgeons (3rd year of training and beyond) performed 143 478
217 (23.9%) operations and 438 less experienced trainee surgeons (1st and 2nd year of
218 training and foundation doctors) performed 24 399 (4.1%) operations.

219

220 First eye surgery was performed in 396 668 patients where 229 447 (57.8%) were female
221 and the median age at surgery was 76.4 years (range 18.1 – 116.6 years). Second eye
222 surgery was performed in 203 782 patients where 120 453 (59.1%) were female and the
223 median age at surgery was 77.4 years (range 18.0 – 112.4 years). Immediate sequential
224 bilateral cataract surgery (ISBCS) was performed in 317 patients. For the 152 257 (34.0%)
225 patients who had surgery to both eyes on separate days during the study period, the
226 median time between the two operations was 4.3 months (range one day to 7.9 years).

227

228 **Intra-ocular lenses (IOL)**

229 IOL were classified according to their design as one-piece or two-piece, and according
230 to the material used (table 1). Twenty-one specific branded models were used, with two
231 IOL models implanted in >100 000 operations each Figure 1. The number of different IOL
232 models used in contributing centres varied considerably, with two (3.4%) centres using
233 only one IOL model, 12 (20.7%) centres three IOL models, 10 (17.2%) centres four IOL
234 models and 34 (58.6%) centres five or more models with one centre having data for 14
235 IOL models.

236

237 **PCO rates**

238 Post-cataract PCO was recorded for 65 210 (10.9%) eyes, with 41 068 (63.0%) of these
239 cases specifically documented as YAG laser being indicated or performed in the same
240 institution that undertook the cataract surgery. The six month, one, three, five and nine
241 year observed rates of PCO were 2.1%, 4.0%, 18.0%, 31.2% and 43.5% respectively.

242 Different PCO profiles were observed between IOL designs and materials, Table 2 and
243 Figure 2.

244

245 **PCO modelling**

246 The covariates considered for the risk factor modelling were grouped into factors related
247 to the IOL, patient factors, cataract surgery and ocular factors. For the individual IOL
248 models there was large variation in the hazard of developing PCO, with some models
249 exhibiting similar patterns to overall and others a virtually flat hazard, potentially related
250 to the tendency for certain IOL to be used predominantly in single centres whose post-
251 operative pathways may be less or more effective at documenting PCO. To circumvent
252 this extreme variation, the individual IOL models were not fitted as a covariate in the
253 risk factor model, instead the IOL material was used.

254

255 At the univariate level all covariates considered for the post-cataract PCO risk factor
256 modelling showed association at the 10% level except for the patient's ability to
257 cooperate ($p = 0.559$), the presence of corneal pathology ($p = 0.318$), the presence of no
258 fundal view / vitreous opacity ($p = 0.380$) and the presence of optic nerve / CNS disease
259 ($p = 0.676$). The final best fitting PCO risk factor model estimates are shown in Table 3.

260

261 Many of the differences for a covariate occur after a period of time has elapsed, for
262 example the statistical difference in PCO rates between the occurrence of PCR and the
263 presence of glaucoma, pseudoexfoliation / phacodonesis or unspecified 'other' ocular
264 co-pathology only becomes apparent after one year post-cataract surgery. The

265 difference between male and female patients, diabetic status, previous anti-VEGF
266 therapy and a brunescant / white / mature cataract occurs after two years post-cataract
267 surgery. For some covariates the PCO rates diverge within the first year post-cataract
268 surgery, for example patient age, first or second eye surgery, axial length, previous
269 vitrectomy surgery and the presence of high myopia or other macular pathology. The
270 risk of developing PCO for eyes with uveitis / synechiae switched at around four years
271 post-cataract surgery, initially increasing the risk of PCO and then appearing to lower
272 the risk.

273

274 The PCO risk factor model was not a perfect fit and the number of significant covariates
275 is a concern regarding possible over-fitting. There was deviation away from the line of
276 identity between the cumulative hazard and the Cox-Snell residuals, although the area
277 of deviation of concern applied to 0.02% of the sample. As a sensitivity analysis the
278 affected operations were removed, the PCO model re-fitted and very similar estimates
279 found for each covariate.

280

281 **Discussion**

282 From the RCOphth NOD Cataract Audit dataset, 601 084 cataract operations performed
283 by 2 566 surgeons in 58 centres were included in this analysis with overall one-, three-,
284 and five-year PCO rates of 4.0%, 18.0% and 31.2% respectively. These figures resonate
285 with other large published series,(3, 4, 6) and indicate the burden placed on patients
286 and services by PCO which can be expected to grow as demand for cataract surgical

287 provision grows over the next two decades.(7) Where opportunities exists to reduce
288 PCO rates, there are strong economic arguments for taking these.(3)

289

290 The risk factors for PCO identified in this study included an axial length >26 mm,
291 presence of high myopia and implantation of lower IOL powers, previous vitrectomy
292 surgery and uveitis/synechia, along with younger age and female gender which could
293 be utilised in the informed consent process.

294

295 **IOL Material**

296 It has been proposed that hydrophilic IOL materials are a risk factor for PCO
297 development. However, a Cochrane collaboration systematic review in 2010 including
298 66 prospective RCTs dealing with potential factors for PCO after cataract surgery failed
299 to demonstrate statistically significant differences between different IOL optic
300 materials, although they did conclude that silicone IOLs seem to have lower PCO rates
301 in several studies and hydrogel (hydrophilic acrylic) IOLs tend to have higher PCO scores
302 than other materials.(2) In the UK, the weight of evidence was insufficient for NICE, in
303 their 2017 cataract guidelines [NG77], to promote the selection of one IOL material over
304 another, although a meta-analysis from 2017, did report hydrophobic intraocular lenses
305 as associated with lower Nd:YAG laser capsulotomy rates compared to hydrophilic
306 lenses (OR = 0.38, (95% CI 0.16-0.91, P = 0.029)).(8) Subsequent case series have also
307 reported significantly higher rates of PCO for hydrophilic IOL,(4, 9). The findings from
308 our study of significantly higher PCO rates with hydrophilic IOL (coefficient -0.741)
309 compared with hydrophobic IOL is consistent with these. A report from Sweden suggests

310 the main attraction of hydrophilic IOL may be economic, and whilst less expensive IOL
311 save money for the surgical provider, the increased PCO rate can be shown to make the
312 overall cost of cataract care at population level more expensive.(3)

313

314 **Age**

315 The association of older age at the time of surgery with progressively lower PCO rates is
316 consistent with other studies.(9, 10) One study estimated that each year of increased
317 age gives an OR for PCO of 0.96 (95% CI 0.92-1.00).(10) The observation that older
318 patients experience less PCO does not, in itself, suggest any potential for reducing PCO
319 rates at population level. However, should interventions that delay the onset of cataract
320 become available, reduced PCO rates promoted by this delay in uptake of surgery may
321 contribute to considerations of their cost-effectiveness.

322

323 **IOL Design**

324 The differences observed between IOL designs should be interpreted with caution.
325 There is clear selection bias in the evaluation of monofocal multipiece IOL, as these are
326 often employed in cases of PC rupture where visually significant PCO is less likely as the
327 PC is already ruptured. The monofocal toric IOL can be expected to be implanted into a
328 population of patients with greater interest in spectacle independence, who may be
329 more proactive in maintaining optimal vision, and hence present at an earlier stage of
330 PCO development. Conclusions around toric IOL are also hampered by their vastly
331 smaller sample size in NHS practice.

332

333 **Differential rates of opacification**

334 The variation over time of the impact of various risk factors requires consideration. For
335 some there is an intuitive explanation, such as uveitic eyes could have an increased
336 inflammatory response following cataract surgery, potentially leading to higher initial
337 PCO rates. However, it may be that uveitic eyes which are destined to get PCO are more
338 likely to get it in the first or second year post-surgery and those eyes which have not
339 developed PCO by three years post-operatively are less likely to subsequently, whereas
340 in non-uveitic eyes the annual risk takes longer to migrate towards zero. This
341 acceleration in accumulation of PCO in uveitis has been reported elsewhere.(9)

342

343 Variation may be due to differences in the ability of clinicians to diagnose, or willingness
344 to treat PCO. Those with small pupils had lower PCO rates, which is counterintuitive as
345 these eyes might have been expected to have more residual soft-lens material at the
346 end of surgery increasing their chances of PCO. A potential explanation would be that
347 small pupils make PCO less visible to an examining clinician, hence reducing their
348 tendency to refer for, or to offer, capsulotomy. Amblyopia was seen to increase rates of
349 PCO; which could be expected as clinicians are unable to be certain whether maximum
350 visual benefits have been gained and are therefore more likely to consider capsulotomy
351 for levels of PCO that would be ignored in non-amblyopic eyes where both clinician and
352 patient are happy with the acuity. People with diabetes had lower PCO rates than those
353 without diabetes, potentially explained by surgeon reluctance to perform YAG laser
354 surgery on people with diabetes for fear of provoking macular oedema. Equally, this
355 seemingly protective effect of diabetes could be due to retention of otherwise

356 uncomplicated post-operative cataract patients in eye care services maintaining a larger
357 denominator, an explanation that would serve equally for the association of lower PCO
358 with glaucoma, age-related macular degeneration and other macular pathologies.

359

360 The higher PCO rate in eyes with an axial length >26 mm and in high myopia is potentially
361 linked to the larger size of the capsular bag producing a less tight apposition of the
362 square posterior edge of the IOL to the capsule reducing the effectiveness of that square
363 edge in preventing posterior migration of lens epithelial cells. A recent meta-analysis
364 showed clear benefit of capsular tension rings in reducing PCO rates, potentially by
365 mitigating for looser fitting capsules,(11) and it may be the use of these rings that
366 explains the reduced PCO rates in eyes with pseudoexfoliation found in this study.

367

368 **Study limitations**

369 The use of routinely collected data, without linkage of health records, limits the inclusion
370 of patients to those who subsequently interact with their cataract surgical provider. In
371 some geographic areas, the assumption patients will remain with the same provider is
372 fairly sound, but in other settings patients move freely between providers for different
373 treatments. Patients who have no further interaction with the cataract surgery provider
374 leave the denominator at their last recorded visit. It is not possible to estimate the
375 extent to which either the departure of PCO-free patients from the series creates a
376 systematic bias towards over-estimation of PCO rates, or systematic under-estimation
377 is produced by patients with PCO remaining undiagnosed, untreated or treated
378 elsewhere. These biases could be reduced if the RCOphth is successful in its application

379 for *section 251 exemption* which will permit repetition of this study with health data
380 linkage between providers and other NHS databases via the NHS number.

381

382 The similarity between our estimates and those of other published series, both RCT (2)
383 and real-world case series,(3, 4, 6) suggests the extent of bias in either direction is
384 acceptable for the purpose of risk factor evaluation, although the caveats need to be
385 considered when citing PCO rates or absolute risks at given time points.

386

387 **Conclusions**

388 Quality in cataract service delivery is a multi-faceted concept. Reducing PCO rates feeds
389 into most of the domains of quality suggested by the WHO (effectiveness, safety,
390 people-centredness, timeliness, equity, integration and efficiency), as well as
391 contributing to the proposed additional domain of planetary health.(12) Whilst the
392 variation in observed PCO rates between centres, coupled with the tendency of many
393 centres to adopt single IOL models for predominant use, prevented conclusions being
394 drawn about individual IOL models, important inferences are still possible.

395

396 Centres should be strongly encouraged to undertake comparison of PCO rates for the
397 different IOL they use, and opt for lenses that minimise the visual loss caused by PCO
398 and the need for subsequent capsulotomy. The cost of YAG laser capsulotomy to the
399 NHS is estimated at £132 per case on average, and it therefore represents a false
400 economy for NHS providers to opt for less expensive IOL with higher PCO rates. Where
401 the purchaser provider split exists, the perverse incentive to ignore PCO rates when

402 procuring IOL needs to be resisted. It may be that commissioners could opt for lowering
403 PCO rates as one aspect of quality on which they base remuneration, or even combine
404 cataract and YAG laser capsulotomy services, such that no independent tariff is
405 associated with the treatment of PCO. The incentive to lower PCO rates would then be
406 universally felt. Future research might involve economic analyses of interventions to
407 reduce PCO rates such as capsule tension ring usage or adoption of IOL designs or
408 models that perform particularly well in subsequent evaluations.

409

410

411 **Acknowledgments**

412 It is with deep regret that we note the death of our friend and colleague Robert
413 Johnston, who sadly died in September 2016. Without his inspirational vision,
414 determination and career long commitment to quality improvement in ophthalmology
415 this work would not have been possible.

416 We acknowledge the support of the hospitals that participated in this National
417 Ophthalmology Database Audit study and thank our medical and non-medical
418 colleagues for the considerable time and effort devoted to data collection.

419 The 58 centres with data in this analysis are listed in alphabetical order below separated
420 into the region they are located in.

421

422 **English NHS Trusts:**

423 Barking, Havering and Redbridge University Hospitals NHS Trust; Barts Health NHS Trust;
424 Bolton NHS Foundation Trust; Bradford Teaching Hospitals NHS Foundation Trust;

425 Calderdale and Huddersfield NHS Foundation Trust; Chesterfield Royal Hospital NHS
426 Foundation Trust; County Durham and Darlington NHS Foundation Trust; East Kent
427 Hospitals University NHS Foundation Trust; East Sussex Healthcare NHS Trust; Epsom
428 and St Helier University Hospitals NHS Trust; Frimley Health NHS Foundation Trust;
429 Gloucestershire Hospitals NHS Foundation Trust; Great Western Hospitals NHS
430 Foundation Trust; Hampshire Hospitals NHS Foundation Trust; Harrogate and District
431 NHS Foundation Trust; Imperial College Healthcare NHS Trust; Isle of Wight NHS Trust;
432 King's College Hospital NHS Foundation Trust; Leeds Teaching Hospitals NHS Trust;
433 Liverpool University Hospitals NHS Foundation Trust; Manchester University NHS
434 Foundation Trust; Mid Cheshire Hospitals NHS Foundation Trust; Mid and South Essex
435 NHS Trust; Moorfields Eye Hospital NHS Foundation Trust*; Norfolk and Norwich
436 University Hospitals NHS Foundation Trust; North Middlesex University Hospital NHS
437 Trust; North West Anglia NHS Foundation Trust; Northern Devon Healthcare NHS Trust;
438 Nottingham University Hospitals NHS Trust; Oxford University Hospitals NHS Foundation
439 Trust; Portsmouth Hospitals NHS Trust; Royal Berkshire NHS Foundation Trust; Royal
440 Cornwall Hospitals NHS Trust; Royal Free London NHS Foundation Trust; Royal United
441 Hospitals Bath NHS Foundation Trust; Salisbury NHS Foundation Trust; Sandwell and
442 West Birmingham Hospitals NHS Trust; Sheffield Teaching Hospitals NHS Foundation
443 Trust; Shrewsbury and Telford Hospital NHS Trust; South Tees Hospitals NHS Foundation
444 Trust; South Warwickshire NHS Foundation Trust; The Hillingdon Hospitals NHS
445 Foundation Trust; The Mid Yorkshire Hospitals NHS Trust; The Newcastle upon Tyne
446 Hospitals NHS Foundation Trust; The Princess Alexandra Hospital NHS Trust; University
447 Hospitals Dorset NHS Foundation Trust; Torbay and South Devon NHS Foundation Trust;

448 University Hospital Southampton NHS Foundation Trust; University Hospitals
449 Birmingham NHS Foundation Trust; University Hospitals Bristol and Weston NHS
450 Foundation Trust; University Hospitals Coventry and Warwickshire NHS Trust; University
451 Hospitals Plymouth NHS Trust; Warrington and Halton Teaching Hospitals NHS
452 Foundation Trust; Wirral University Teaching Hospital NHS Foundation Trust;
453 Wrightington, Wigan and Leigh NHS Foundation Trust; Yeovil District Hospital NHS
454 Foundation Trust;

455

456 **Welsh Local Health Boards:**

457 Cardiff & Vale University Local Health Board;

458

459 **Guernsey:**

460 Medical specialists group Guernsey;

461 *Includes data from Bedfordshire Hospitals NHS Foundation Trust and Croydon Health
462 Services NHS Trust as the ophthalmology services for these two NHS Trusts are part of
463 Moorfields Eye Hospital NHS Foundation Trust.

464

465

466 **Table and Figure legends**

467 **Table 1:**

468 Use of IOL design and materials in centres, for operations, surgeons, time period of use
469 and median age of patients

470

471 *Excluding simultaneous bilateral cataract surgery as some patients had different IOL's
472 from different IOL design and IOL material used in each eye. For patients who have had
473 both eyes operated on different dates, their age at each surgery is considered as
474 separate events. N = 600

475

476 450 operations from 448 193 patients, where 152 257 patients had surgery to both eyes
477 on different dates.

478

479

480 **Table 2:**

481 Observed PCO rates at specified post-cataract surgery for the IOL design and material

482

483

484 **Table 3:**

485 PCO risk factor model estimates

486

487 *When the covariate coefficient is negative this implies a higher risk of PCO, and when
488 the covariate coefficient is positive this implies a lower risk of PCO. Each covariate has a
489 reference category with a coefficient of zero, thus the closer a covariate category
490 coefficient is to zero, the less difference there is between this category and the
491 reference category, for example increasing age implies lower risk of PCO as can be seen
492 from the larger positive coefficients for each successive older age group.

493

494


495 **Figure 1:**

496 The number of operations in the sample where each IOL model was used. N = 601 084

497 cataract operations performed by 2 566 surgeons from 58 centres

498

499




500 **Figure 2:**

501 Kaplan-Meier failure plot of time to post-cataract PCO for the IOL material. N = 601 084

502 cataract operations performed by 2 566 surgeons from 58 centres

503



504

505 **References**

506

- 507 1. Maedel S, Evans JR, Harrer-Seely A, Findl O. Intraocular lens optic edge design for the
508 prevention of posterior capsule opacification after cataract surgery. The Cochrane database of
509 systematic reviews. 2021;8:CD012516.
- 510 2. Findl O, Buehl W, Bauer P, Sycha T. Interventions for preventing posterior capsule
511 opacification. The Cochrane database of systematic reviews. 2010(2):CD003738.
- 512 3. Cullin F, Busch T, Lundstrom M. Economic considerations related to choice of intraocular
513 lens (IOL) and posterior capsule opacification frequency - a comparison of three different IOLs.
514 Acta Ophthalmol. 2014;92(2):179-83.
- 515 4. Ursell PG, Dhariwal M, Majirska K, Ender F, Kalson-Ray S, Venerus A, et al. Three-year
516 incidence of Nd:YAG capsulotomy and posterior capsule opacification and its relationship to
517 monofocal acrylic IOL biomaterial: a UK Real World Evidence study. Eye (Lond).
518 2018;32(10):1579-89.
- 519 5. Buchan JC, Donachie PHJ, Cassels-Brown A, Liu C, Pyott A, Yip JLY, et al. The Royal College
520 of Ophthalmologists' National Ophthalmology Database study of cataract surgery: Report 7,
521 immediate sequential bilateral cataract surgery in the UK: Current practice and patient selection.
522 Eye (Lond). 2020;34(10):1866-74.
- 523 6. Johansson B. Clinical consequences of acrylic intraocular lens material and design:
524 Nd:YAG-laser capsulotomy rates in 3 x 300 eyes 5 years after phacoemulsification. Br J
525 Ophthalmol. 2010;94(4):450-5.
- 526 7. Buchan JC, Amoaku W, Barnes B, Cassels-Brown A, Chang BY, Harcourt J, et al. How to
527 defuse a demographic time bomb: the way forward? Eye (Lond). 2017;31(11):1519-22.

- 528 8. Zhao Y, Yang K, Li J, Huang Y, Zhu S. Comparison of hydrophobic and hydrophilic
529 intraocular lens in preventing posterior capsule opacification after cataract surgery: An updated
530 meta-analysis. *Medicine (Baltimore)*. 2017;96(44):e8301.
- 531 9. Tokko HA, Hussain F, Al-Awadi A, Mei F, Zeiter JH, Kim C, et al. Factors Associated with
532 the Development of Posterior Capsule Opacification Requiring Yttrium Aluminum Garnet
533 Capsulotomy. *Optometry and vision science : official publication of the American Academy of*
534 *Optometry*. 2019;96(7):492-9.
- 535 10. Prajna NV, Ellwein LB, Selvaraj S, Manjula K, Kupfer C. The madurai intraocular lens study
536 IV: posterior capsule opacification. *Am J Ophthalmol*. 2000;130(3):304-9.
- 537 11. Zhang K, Dong Y, Zhao M, Nie L, Ding X, Zhu C. The effect of capsule tension ring on
538 posterior capsule opacification: A meta-analysis. *PLoS One*. 2021;16(3):e0246316.
- 539 12. Yoshizaki M, Ramke J, Zhang JH, Aghaji A, Furtado JM, Burn H, et al. How can we improve
540 the quality of cataract services for all? A global scoping review. *Clinical & experimental*
541 *ophthalmology*. 2021;49(7):672-85.
- 542

543

544 **Table 1: Use of IOL design and materials in centres, for operations, surgeons, time**
545 **period of use and median age of patients**

546

	Number of centres	Number of operations	Number of surgeons	Time span of use (years)	Median age of patients*
IOL design					
Monofocal Single Piece	58	568 162	2 536	8.0	76.8
Monofocal Multipiece	49	30 553	1 560	8.0	76.2
Monofocal Toric	20	2 369	435	8.0	73.1
IOL material					
Hydrophobic	54	371 330	2 065	8.0	76.8
Hydrophilic	40	157 646	1 368	8.0	76.7
Silicone	24	36 485	609	8.0	77.1
Hydrophobic / PMMA	49	30 553	1 560	8.0	76.2
Hydrophobic / Hydrophilic	9	5 070	70	6.2	77.5
Overall	58	601 084	2 566	8.0	76.7

547

548 *Excluding simultaneous bilateral cataract surgery as some patients had different IOL's
549 from different IOL design and IOL material used in each eye. For patients who have had
550 both eyes operated on different dates, their age at each surgery is considered as
551 separate events.

552

553

554 Table 2: Observed PCO rates at specified post-cataract surgery for the IOL design and
 555 material
 556

	6 months	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years
Total	601 084	355 189	276 973	192 700	125 461	80 364	50 073	28 897	14 800
Number of PCO cases since previous time point	9 947	6 383	14 444	15 195	9 811	5 223	2 492	1 127	440
Rate (N = 601 084)	2.1	4.0	9.7	18.0	25.4	31.2	35.4	38.6	41.0
Single Piece PCO (N = 568 162)	2.1	4.1	10.0	18.6	26.3	32.2	36.5	39.8	42.0
Multipiece PCO (N = 30 553)	1.8	3.1	5.7	9.2	13.0	17.0	20.7	23.7	26.0
Hydrophilic PCO (2 369)	2.3	3.8	10.1	19.2	30.2	40.6	51.3	58.4	61.0
PMMA PCO (N = 371 330)	1.7	3.3	6.8	12.0	18.0	23.7	28.3	31.9	34.0
Hydrophobic PCO (N = 157 646)	3.1	6.0	17.0	31.9	43.0	50.0	54.3	57.4	59.0
Hydrophilic PCO (N = 36 485)	1.7	3.0	6.0	10.4	14.4	17.6	20.4	23.0	25.0
PMMA PCO (N = 30 553)	1.8	3.1	5.7	9.2	13.0	17.0	20.7	23.7	26.0
Hydrophilic PCO (N = 5 070)	2.1	4.6	18.8	42.5	61.0	67.4	67.4	67.4	-

557

558

559 Table 3: PCO risk factor model estimates

560

PCO risk factor model covariate*	Coefficient	Standard error	p-value	95% Confidence Interval
Gamma	0.707	0.002	<0.001	0.702 to 0.711
Constant	1.946	0.050	<0.001	1.848 to 2.044
IOL material				
Hydrophobic	0.000	Reference	Reference	Reference
Hydrophilic	-0.741	0.008	<0.001	-0.756 to -0.726
Silicone	0.235	0.017	<0.001	0.201 to 0.269
Hydrophobic / PMMA	0.246	0.018	<0.001	0.210 to 0.281
Hydrophobic / Hydrophilic	-0.927	0.024	<0.001	-0.974 to -0.880
IOL power (dioptres)				
<15	-0.155	0.020	<0.001	-0.194 to -0.115
15 to 19.5	-0.042	0.009	<0.001	-0.060 to -0.025
20 to 28.5	0.000	Reference	Reference	Reference
29 to 40	-0.034	0.026	0.192	-0.085 to 0.017
Age at surgery (years)				
<40	0.000	Reference	Reference	Reference
40 – 49	0.354	0.052	<0.001	0.252 to 0.456
50 – 89	0.630	0.046	<0.001	0.540 to 0.720
≥90	0.718	0.051	<0.001	0.619 to 0.818
Gender				
Female	0.000	Reference	Reference	Reference
Male	0.099	0.007	<0.001	0.084 to 0.114
Diabetic status				
No diabetes	0.000	Reference	Reference	Reference
Diabetic	0.144	0.009	<0.001	0.127 to 0.162
Grade of operating surgeon				
Consultant surgeon	0.000	Reference	Reference	Reference
Career grade non-consultant surgeon	-0.030	0.010	0.003	-0.050 to -0.010
More experienced trainee surgeon	0.025	0.008	0.002	0.009 to 0.041
Less experienced trainee surgeon	-0.024	0.017	0.155	-0.057 to 0.009

First / second eye surgery				
First eye surgery	0.000	Reference	Reference	Reference
Second eye surgery	-0.137	0.006	<0.001	-0.149 to -0.126
PCR occurring during surgery				
No	0.000	Reference	Reference	Reference
Yes	0.384	0.038	<0.001	0.309 to 0.458
Pupil size				
Small	0.000	Reference	Reference	Reference
Medium	-0.091	0.018	<0.001	-0.127 to -0.055
Large	-0.034	0.018	0.055	-0.069 to 0.001
Missing	1.519	0.093	<0.001	1.335 to 1.702
Axial length (mm)				
<26	0.000	Reference	Reference	Reference
≥26	-0.079	0.022	<0.001	-0.122 to -0.036
Missing	0.410	0.018	<0.001	0.375 to 0.445
Anti-VEGF therapy				
No previous Anti-VEGF therapy	0.000	Reference	Reference	Reference
Anti-VEGF therapy	0.121	0.020	<0.001	0.083 to 0.160
The presence of any of the following				
Age-related macular degeneration	0.046	0.011	<0.001	0.024 to 0.069
Brunescent / white / mature cataract	0.065	0.019	0.001	0.028 to 0.103
Glaucoma	0.298	0.011	<0.001	0.278 to 0.319
High myopia	-0.076	0.019	<0.001	-0.113 to -0.040
Other macular pathology	-0.128	0.019	<0.001	-0.166 to -0.091
Pseudoexfoliation / Phacodonesis	0.206	0.034	<0.001	0.140 to 0.272
Previous vitrectomy surgery	-0.621	0.020	<0.001	-0.662 to -0.581
Uveitis / synechiae	-0.083	0.030	0.006	-0.143 to -0.024
Unspecified 'other' co-pathology	-0.088	0.013	<0.001	-0.112 to -0.063

561

562 *When the covariate coefficient is negative this implies a higher risk of PCO, and when
563 the covariate coefficient is positive this implies a lower risk of PCO. Each covariate has a
564 reference category with a coefficient of zero, thus the closer a covariate category

565 coefficient is to zero, the less difference there is between this category and the
566 reference category, for example increasing age implies lower risk of PCO as can be seen
567 from the larger positive coefficients for each successive older age group.

568

569